Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for ...

Patrick J McEnany, Board Member at Catalyst Pharmaceuticals CPRX, reported an insider sell on November 13, according to a new SEC filing. Tracking the Thursday's morning session, Catalyst ...

NasdaqCM:CPRX Earnings and Revenue History November 13th 2024 Examining Cashflow Against Catalyst Pharmaceuticals' Earnings. One key financial ratio used to measure how well a com ...

Truist Financial analyst Joon Lee reiterated a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Catalyst Pharmaceuticals Inc (CPRX) reports a 25.3% increase in total revenue and updates its full-year guidance, while ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Q3 2024 Earnings Call Transcript November 7, 2024 Operator: Thank you for standing by. My name is Kris and I will be your ...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good ...

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently filed a Form 8-K with the Securities and Exchange Commission, detailing its financial performance for the third quarter of 2024. The company ...